Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry

AAPS Journal

Volumn 8, Issue 4, 2006, Pages

  Wei, Xiaohui ^a   Dai, Guowei ^b   Liu, Zhongfa ^a   Cheng, Hao ^a   Xie, Zhiliang ^a   Marcucci, Guido ^c,d   Chan, Kenneth K ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

GTI 2040; Liquid chromatography mass spectrometry; Metabolism; Phosphorothioate oligonucleotides

Indexed keywords

DRUG METABOLITE; EXONUCLEASE; GTI 2040; ANTISENSE OLIGONUCLEOTIDE; PHOSPHATE; PHOSPHORODITHIOIC ACID; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; ENZYME MECHANISM; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ION PAIR CHROMATOGRAPHY; KIDNEY PARENCHYMA; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER PARENCHYMA; MOUSE; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TISSUE SPECIFICITY; ANIMAL; CATTLE; COMPARATIVE STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; METHODOLOGY; SNAKE;

ANIMALS; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATES; SNAKES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33846077453     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080484     Document Type: Article

References (46)

1. Crooke ST. Progress in antisense technology. Annu Rev Med. 2004;55:61-95.
2. Griffey RH, Greig MJ, Gaus HJ, et al. Characterization of oligonucleotide metabolism in vivo via liquid chromatography/ electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer. J Mass Spectrom. 1997;32:305-313.
3. Geary RS, Watanabe TA, Truong L, et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther. 2001;296:890-897.
4. Yu RZ, Zhang H, Geary RS, et al. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther. 2001;296:388-395.
5. Raynaud FI, Orr RM, Goddard PM, et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997;281:420-427.
6. Kurreck J. Antisense technologies: improvement through novel chemical modifications. Eur J Biochem. 2003;270:1628-1644.
7. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA. 1991;88:7595-7599.
8. Cossum PA, Sasmor H, Dellinger D, et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993;267:1181-1190.
9. Crooke ST, Graham MJ, Zuckerman JE, et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther. 1996;277:923-937.
10. Leeds JM, Graham MJ, Truong L, Cummins LL. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem. 1996;235:36-43.
11. Gaus HJ, Owens SR, Winniman M, Cooper S, Cummins LL. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem. 1997;69:313-319.
12. Gilar M. Analysis and purification of synthetic oligonucleotides by reversed-phase high-performance liquid chromatography with photodiode array and mass spectrometry detection. Anal Biochem. 2001;298:196-206.
13. Lichtenwalter KG, Apffel A, Bai J, et al. Approaches to functional genomics: potential of matrix-assisted laser desorption ionization - time of flight mass spectrometry combined with separation methods for the analysis of DNA in biological samples. J Chromatogr B Biomed Sci Appl. 2000;745:231-241.
14. Gilar M, Bouvier ESP. Purification of crude DNA oligonucleotides by solid-phase extraction and reversed-phase high-performance liquid chromatography. J Chromatogr A. 2000;890:167-177.
15. Ni J, Pomerantz C, Rozenski J, Zhang Y, McCloskey JA. Interpretation of oligonucleotide mass spectra for determination of sequence using electrospray ionization and tandem mass spectrometry. Anal Chem. 1996;68:1989-1999.
16. Crooke RM, Graham MJ, Martin MJ, Lemonidis KM, Wyrzykiewiecz T, Cummins LL. Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther. 2000;292:140-149.
17. Dai G, Wei X, Liu Z, Liu S, Marcucci G, Chan KK. Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;825:201-213.
18. Murphy AT, Brown-Augsburger P, Yu RZ, Geary RS, Thibodeaux S, Ackermann BL. Development of an ion-pair reverse-phase liquid chromatographic/ tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissue. Eur J Mass Spectrom (Chichester Eng). 2005;11:209-215.
19. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer. 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 1997;12:383-393.
20. Temsamani J, Tang JY, Padmapriya A, Kubert M, Agrawal S. Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev. 1993;3:277-284.
21. Temsamani J, Roskey A, Chaix C, Agrawal S. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Antisense Nucleic Acid Drug Dev. 1997;7:159-165.
22. Gilar M, Belenky A, Budman Y, Smisek DL, Cohen AS. Study of phosphorothioate-modified oligonucleotide resistance to 3′-exonuclease using capillary electrophoresis. J Chromatogr B Biomed Sci Appl. 1998;714:13-20.
23. Graham MJ, Crooke ST, Lemonidis KM, Gans HJ, Templin MV, Crooke RM. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol. 2001;62:297-306.
24. Noll BO, McCluskie MJ, Sniatala T, et al. Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol. 2005;69:981-991.
25. Crooke RM, Graham MJ, Cooke ME, Crooke ST. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther. 1995;275:462-473.
26. Gilar M, Belenky A, Budman Y, Smisek DL, Cohen AS. Impact of 3′-exonuclease stereoselectivity on the kinetics of phosphorothioate oligonucleotide metabolism. Antisense Nucleic Acid Drug Dev. 1998;8:35-42.
27. Graham MJ, Crooke ST, Monteith DK, et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther. 1998;286:447-458.
28. Koziolkiewicz M, Wojcik M, Kobylanska A, et al. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3′-exonuclease. Antisense Nucleic Acid Drug Dev. 1997;7:43-48.
29. Lee Y, Vassilakos A, Feng N, et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res. 2003;63:2802-2811.
30. Desai AA, Schilsky RL, Young A, et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005;16:958-965.
31. Liu Z, Minkler PE, Lin D, Sayre LM. Derivatization of amino acids with N,N-dimethyl-2,4-dinitro-5-fluorobenzylamine for liquid chromatography/ electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2004; 18:1059-1065.
32. Liu Z, Floss HG, Cassady JM, Chan KK. Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 2005;40:389-399.
33. Cohen AS, Bourque AJ, Wang BH, Smisek DL, Belenky A. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997;7:13-22.
34. Rozenski J, McCloskey JA. SOS: a simple interactive program for ab initio oligonucleotide sequencing by mass spectrometry. J Am Soc Mass Spectrom. 2002;13:200-203.
35. McLuckey SA, Goeringer DE, Glish GL. Collisional activation with random noise in ion trap mass spectrometry. Anal Chem. 1992;64:1455-1460.
36. McLuckey SA, Glish GL, Van Berkel GJ. Charge determination of product ions formed from collision-induced dissociation of multiply protonated molecules via ion/molecule reactions. Anal Chem. 1991;63:1971-1978.
37. Apffel A, Chakel JA, Hancock WS, Souders C. M'Timkulu T, Pungor E Jr. Application of multidimensional affinity high-performance liquid chromatography and electrospray ionization liquid chromatography-mass spectrometry to the characterization of glycosylation in single-chain plasminogen activator: initial results. J Chromatogr A. 1996;750:35-42.
38. Huber CG, Oefner PJ, Bonn GK. High-resolution liquid chromatography of oligonucleotides on nonporous alkylated styrene-divinylbenzene copolymers. Anal Biochem. 1993;212:351-358.
39. Kuklin A, Munson K, Gjerde D, Haefele R, Taylor P. Detection of single-nucleotide polymorphisms with the WAVE DNA fragment analysis system. Genet Test.. 1998;1:201-206.
40. Geary RS, Yu RZ, Leeds JM, Watanabe TA, Henry SP, Levin AA, eds. Pharmacokinetic properties in animals. In: Crooke ST, ed. Antisense Drug Technology. New York, NY: Marcel Dekker, Inc.; 2001:139-141.
41. Geary RS, Leeds JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos. 1997;25:1272-1281.
42. Geary RS, Yu RZ, Levin AA. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs. 2001;2:562-573.
43. Butler M, Stecker K, Bennett CF. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest. 1997;77:379-388.
44. Iversen P. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des. 1991;6:531-538.
45. Lorus Therapeutics. GTI-2040 Investigator Brochure. Toronto, Canada: Lorus Therapeutics, Inc.; 1999.
46. Sawai K, Mahato RI, Oka Y, Takakura Y, Hashida M. Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther. 1996;279:284-290.